



Study Title:	A Supportive Care Trial for Cardiotoxicity in Women with Breast Cancer
Scientific Title:	SCUSF 0806-Phase II Randomized Study of Lisinopril or Carvedilol Phosphate Extended-Release in Reducing Cardiotoxicity in Women with HER2-Positive Breast Cancer Receiving Adjuvant or Neoadjuvant Trastuzumab
Department and/or Specialty:	RCC-Breast-Supportive Care
Investigator:	Michael Thompson, MD, PhD
Contact Information:	Chanda Miller 262-928-5539
<p>Lisinopril or carvedilol phosphate may help reduce side effects caused by trastuzumab. It is not yet known whether lisinopril or carvedilol phosphate are more effective than a placebo in reducing side effects caused by trastuzumab.</p> <p>This phase ii trial is studying lisinopril and carvedilol phosphate to see how well they work compared with a placebo in reducing side effects in women with HER2 –positive breast cancer receiving trastuzumab.</p>	



PROHEALTH CARE
RESEARCH INSTITUTE